Marianne Elaine McPherson Yee

Marianne Elaine McPherson Yee

Auto-generated profile, based on publicly available information

Marianne Elaine McPherson Yee

Aflac Cancer and Blood Disorders Center Children's Healthcare of Atlanta Atlanta Georgia USA

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 April 2020 in Blood Advances
Verified
Journal Article
Open access
PDF file
ONOmar Niss
Omar Niss
ALAdam Lane
Adam Lane
MMonika Asnani
Monika Asnani
MYMarianne E. Yee
Marianne E. Yee
ARAshok Raj
Ashok Raj
PMPunam Malik
Punam Malik
Sickle cell nephropathy results in chronic kidney disease (CKD), which is associated with significant morbidity and mortality in sickle cell anemia (SCA). Albuminuria is an early manifestation of sickle nephropathy; however, little is known about progression of albuminuria or its correlation with glomerular filtration rate (GFR) decline or CKD. We studied nephropathy progression in 303 SCA participants in a prospective, multicenter, longitudinal study. We collected steady-state urine and serum samples yearly and assessed albumin/creatinine ratio (ACR), estimated GFR (eGFR), and SCA and nephropathy biomarkers. Participants with albuminuria (ACR ≥30 mg/g) for ≥2 annual measurements were classified as having persistent albuminuria (PA). At baseline (mean age, 21 years; range, 2-64 years), 32% had albuminuria. In longitudinal multivariate analysis, ACR was associated with sex, anemia, older age, and higher bilirubin and kidney injury molecule-1 levels. Albuminuria increased with age by 3.5 mg/g per year (P < .0001). Of 175 participants with ≥3 annual samples, 81% with baseline albuminuria ≥100 mg/g developed PA. Decreased eGFR and adult CKD were associated with PA (P = .002 and P = .02, respectively), but not with baseline albuminuria. Rate of eGFR decline was steeper among adults (but not children) with albuminuria, compared with those without (P = .02). Participants with PA were more likely to have rapid eGFR decline compared with those without (P = .03). In this longitudinal study, albuminuria progressed with age, and adults with albuminuria had worse eGFR decline than those without. Albuminuria ≥100 mg/g predicted PA, which was associated with rapid eGFR decline and CKD development in adults with SCA. This trial was registered at www.clinicaltrials.gov as #NCT02239016.

14 February 2018 in American Journal of Hematology
Verified
Journal Article
Closed access
PDF file
ESEyal Sagiv
Eyal Sagiv
RFRoss M. Fasano
Ross M. Fasano
NLNaomi L. C. Luban
Naomi L. C. Luban
CJCassandra D. Josephson
Cassandra D. Josephson
SSSean R. Stowell
Sean R. Stowell
MYMarianne E. M. Yee
Marianne E. M. Yee

24 August 2017 in Transfusion
Verified
Journal Article
Closed access
PDF file
MYMarianne E.M. Yee
Marianne E.M. Yee
CJCassandra D. Josephson
Cassandra D. Josephson
AWAnne M. Winkler
Anne M. Winkler
JWJennifer Webb
Jennifer Webb
NLNaomi L.C. Luban
Naomi L.C. Luban
RFRoss M. Fasano
Ross M. Fasano

1 March 2018 in Blood Cells, Molecules, and Diseases
Verified
Journal Article
Closed access
MYMarianne E. Yee
Marianne E. Yee
PLPeter A. Lane
Peter A. Lane
DADavid R. Archer
David R. Archer
CJClinton H. Joiner
Clinton H. Joiner
JEJames R. Eckman
James R. Eckman
AGAntonio Guasch
Antonio Guasch

30 January 2024 in Transfusion
Verified
Journal Article
Closed access
NINarek Israelyan
Narek Israelyan
SVSunitha Vege
Sunitha Vege
DFDavid F. Friedman
David F. Friedman
ZZZhe Zhang
Zhe Zhang
SUStacey Uter
Stacey Uter
SCStella T. Chou
Stella T. Chou

1 October 2013 in Journal of Pediatric Hematology/Oncology
Verified
Journal Article
Closed access
MYMarianne M. Md Yee
Marianne M. Md Yee
CJCassandra Josephson
Cassandra Josephson
CHCharles E. Hill
Charles E. Hill
RHRosiland Harrington
Rosiland Harrington
MCMarta-Inés Bsn Castillejo
Marta-Inés Bsn Castillejo
IOIfeyinwa Osunkwo
Ifeyinwa Osunkwo
The opioid medications codeine and hydrocodone, commonly prescribed in sickle cell disease (SCD), require metabolic conversion by cytochrome P450 2D6 (CYP2D6) to morphine and hydromorphone, respectively, to exert their analgesic effects. The CYP2D6 gene is highly polymorphic, with variant alleles that result in decreased, absent, or ultrarapid enzyme activity. Seventy-five children with SCD were tested for CYP2D6 polymorphisms, and metabolic phenotypes were inferred from the genotypes. The most common variant alleles were CYP2D6*2 (normal activity, 28.7%), CYP2D6*17 (reduced activity, 17.3%), CYP2D6*5 (gene deletion, 8.7%), and CYP2D6*4 (absent function, 8.0%). Normal/extensive metabolizer genotypes were found in 28/75 (37.5%), intermediate metabolism in 33/75 (44.0%), poor metabolism in 4/75 (5.3%), ultrarapid metabolism in 3/75 (4.0%), indeterminate in 6/75 (8.0%). Allele frequencies did not vary significantly among different hemoglobin genotypes. Identification of variant CYP2D6 genotypes may identify individuals with altered metabolism and therefore altered analgesic response to codeine and hydrocodone, thus providing a personalized medicine approach to treatment of pain in SCD. Further pharmacokinetic and pharmacodynamic studies are needed to define the relationship of CYP2D6 and other gene polymorphisms to individual opioid effect in SCD.